Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Heather, Giles"'
Publikováno v:
The Korean Journal of Pain
Background Management of pain from open wounds is a growing unmet healthcare need. However, the models available to study pain from wounds or to develop analgesics for the patients suffering from them have primarily relied on incisional models. Here,
Autor:
Heather Giles, Richard A. Bond
Publikováno v:
Behavioural Pharmacology. 22:385-389
The acute and chronic effects of certain drugs can often be opposite. For example, in congestive heart failure acute administration of β-adrenoceptor agonists results in a beneficial improvement in symptoms of the disease, but their chronic use incr
Autor:
Terry P. Kenakin, David W. Gray, Jim Coote, Alan Wise, Heather Giles, Cynthia L. Burns-Kurtis, Sara Pritchard, Noel Lloyd Staton, Jason D. Brown, Richard J. Wilson, Valerie Morrison, Susan Roomans, Sharron A. Rhodes, Kerri Ann Cartwright, Gerard Martin Paul Giblin, Jannatara Chowdhury, Vanessa J. Shield
Publikováno v:
British Journal of Pharmacology. 148:326-339
1. N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl}benzene sulphonamide (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptors with additional human TP receptor affinity. 2. At r
Autor:
Heather Giles, Richard J. Wilson
Publikováno v:
British Journal of Pharmacology. 144:405-415
1 Prostaglandin E2 produced endothelium-independent relaxation of phenylephrine- and 5-HT-contracted piglet saphenous vein (PSV; pEC50=8.6±0.2; n=6). 2 The prostanoid EP4 receptor antagonist GW627368X (30–300 nM) produced parallel rightward displa
Autor:
David W. Gray, Richard L. Wood, Heather Giles, Vanessa J. Shield, L. Staton Noel, Richard J. Wilson, Sharron A. Rhodes
Publikováno v:
European Journal of Pharmacology. 501:49-58
Prostanoid EP(2) and EP(4) receptor-mediated responses are difficult to distinguish pharmacologically because of the lack of potent, selective antagonists. We describe systematic agonist fingerprints for recombinant human prostanoid EP(2) and EP(4) r
Autor:
Richard A. Bond, Donald L Cuba, Noornabi Dudekula, Kenda L. J. Evans, Brian J. Knoll, Heather Giles, Felix R. Shardonofsky, Zsuzsanna Callaerts-Vegh, Patrick Callaerts
Publikováno v:
Proceedings of the National Academy of Sciences. 101:4948-4953
The clinical effects of treatment withn β-adrenoceptor (β-AR) agonists and antagonists in heart failure vary with duration of therapy, as do the effects of β-AR agonists in asthma. Therefore, we hypothesized that chronic effects of “β-blockers
Autor:
Carol Bronze, Dolores Conroy, Michele Acton, Katherine Cowan, Heather Giles, Mark Fenton, Michael Bowen, Richard Wormald, Fiona J. Rowe, Karen Bonstein, Anita Lightstone, Heather Waterman, Catey Bunce, Kathy Evans, Antra Zekite, Iris Gordon, Louise Halfhide, Robert Harper, Marcela Votruba, Richard Cable
Publikováno v:
BMJ Open
Objectives: The Sight Loss and Vision Priority Setting Partnership aimed to identify research priorities relating to sight loss and vision through consultation with patients, carers and clinicians. These priorities can be used to inform funding bodie
Publikováno v:
British Journal of Pharmacology. 126:810-818
The effect of interleukin-8 (IL-8) and growth-related oncogene alpha (GROalpha) on [35S]-guanosine 5'-O-(3-thiotriphosphate) ([35S]GTPgammaS) binding, forskolin-stimulated cyclic AMP accumulation and cytosolic calcium concentration were determined in
Publikováno v:
Biochemical Pharmacology. 56:1167-1174
The activation of G-proteins by melatonin mt1 receptors was studied by measuring [35S]-guanosine-5'-(3-thiotriphosphate) ([35S]-GTPgammaS) binding to membranes prepared from Chinese hamster ovary (CHO) cells stably expressing human mt1 receptors. Mel
Autor:
A C Honey, S Moncada, D.J. Prentice, S J MacLennan, V J Barrett, Graeme R. Martin, Alan D. Robertson, Buckingham J, Heather Giles
Publikováno v:
British Journal of Pharmacology. 121:157-164
311C90 (zolmitriptan zomig: (S)-4[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone) is a novel 5-HT1B/1D receptor agonist with proven efficacy in the acute treatment of migraine. Here, we describe the receptor specificity of the drug